Verastem Oncology to Participate in Upcoming Investor Conferences

10/31/24 7:30:00 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $VSTM alert in real time by email

Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that its management team will participate in the following upcoming investor conferences:

2024 Truist Securities BioPharma Symposium on November 7, 2024
Guggenheim Healthcare Innovation Conference; fireside chat on Wednesday, November 13, 2024 at 9:00 am EDT

A live webcast of the fireside chat can be accessed under "Events & Presentations" in the Investors & Media section of the company's website at www.verastem.com. A replay of the webcast will be archived on the website for approximately 90 days following the presentation.

About Verastem Oncology

Verastem Oncology (NASDAQ:VSTM) is a late-stage development biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with cancer. Our pipeline is focused on RAS/MAPK-driven cancers, specifically novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including RAF/MEK inhibition and FAK inhibition. For more information, please visit www.verastem.com and follow us on LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241030694764/en/

Get the next $VSTM alert in real time by email

Recent Analyst Ratings for

$VSTM

Date	Price Target	Rating	Analyst
9/30/2024	$13.00	Buy	Guggenheim
11/21/2023	$27.00	Buy	BTIG Research
9/27/2023	$21.00	Buy	B. Riley Securities
6/15/2023	$24.00 → $36.00	Neutral → Buy	Mizuho
9/7/2022	$6.00	Buy	Alliance Global Partners
4/29/2022	$6.00 → $5.00	Overweight	Cantor Fitzgerald
4/14/2022	$5.00	Outperform	RBC Capital Mkts
3/9/2022	$6.00	Buy	Truist

More analyst ratings

Verastem Oncology to Participate in Upcoming Investor Conferences

Chat with this insight

Recent Analyst Ratings for $VSTM

$VSTM Press Releases

Fastest customizable press release news feed in the world

Verastem Oncology Completes Rolling NDA Submission to the FDA for Avutometinib Plus Defactinib as a Treatment for Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer

Verastem Oncology to Participate in Upcoming Investor Conferences

Verastem Oncology Presents Positive Updated RAMP 201 Data for Avutometinib and Defactinib Combination in Recurrent Low-Grade Serous Ovarian Cancer at the International Gynecologic Cancer Society (IGCS) 2024 Annual Meeting

$VSTM Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Rowinsky Eric K bought $7,680 worth of shares (2,000 units at $3.84) (SEC Form 4)

$VSTM Leadership Updates

Live Leadership Updates

Verastem Oncology Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates

Verastem Oncology Announces Appointment of John Hayslip, M.D., to Chief Medical Officer

Verastem Oncology Announces Promotion of Dan Paterson to Chief Executive Officer

$VSTM SEC Filings

Verastem Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

SEC Form 10-Q filed by Verastem Inc.

Verastem Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

$VSTM Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Guggenheim initiated coverage on Verastem with a new price target

BTIG Research resumed coverage on Verastem with a new price target

B. Riley Securities initiated coverage on Verastem with a new price target

$VSTM Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G filed by Verastem Inc.

SEC Form SC 13G/A filed by Verastem Inc. (Amendment)

SEC Form SC 13G/A filed by Verastem Inc. (Amendment)

$VSTM Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Chief Financial Officer Calkins Daniel sold $17 worth of shares (6 units at $2.86), decreasing direct ownership by 0.01% to 47,461 units (SEC Form 4)

Chief Financial Officer Calkins Daniel sold $257 worth of shares (93 units at $2.76), decreasing direct ownership by 0.20% to 47,467 units (SEC Form 4)

Director Gagnon Robert E. sold $365 worth of shares (131 units at $2.79), decreasing direct ownership by 0.37% to 34,892 units (SEC Form 4)

$VSTM Financials

Live finance-specific insights

Verastem Oncology Presents Positive Updated RAMP 201 Data for Avutometinib and Defactinib Combination in Recurrent Low-Grade Serous Ovarian Cancer at the International Gynecologic Cancer Society (IGCS) 2024 Annual Meeting

Verastem Oncology Announces Details for the Oral Presentation of the Mature RAMP 201 Data Evaluating Avutometinib Plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer at the IGCS 2024 Annual Meeting

Verastem Oncology Announces the Initiation of a Rolling Submission of NDA to FDA Seeking Accelerated Approval of Avutometinib and Defactinib Combination for the Treatment of Adult Patients with Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer

$VSTM Market Insights

Live Market Insights

Why General Dynamics Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

Verastem shares are trading lower after the company announced it priced its $55 million public offering of 13,333,334 of its common stocks and accompanying warrants at $3.00 per share and accompanying warrant.

Why Enphase Energy Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket

Recent Analyst Ratings for
$VSTM

$VSTM
Press Releases

$VSTM
Insider Purchases

$VSTM
Leadership Updates

$VSTM
SEC Filings

$VSTM
Analyst Ratings

$VSTM
Large Ownership Changes

$VSTM
Insider Trading

$VSTM
Financials

$VSTM
Market Insights